NYSEAMERICAN:HEB Hemispherx BioPharma (HEB) Stock Price, News & Analysis $6.70 -1.68 (-20.05%) As of 06/13/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartSEC FilingsBuy This Stock About Hemispherx BioPharma Stock (NYSEAMERICAN:HEB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Hemispherx BioPharma alerts:Sign Up Key Stats Today's Range$5.80▼$9.0050-Day Range$6.70▼$6.7052-Week Range$1.69▼$14.81Volume7,639 shsAverage Volume102,599 shsMarket Capitalization$16.36 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Hemispherx BioPharma, Inc. (NYSEAMERICAN:HEB) is a U.S.-based biopharmaceutical company focused on the development and commercialization of immunotherapeutic products for the treatment of viral infections, cancers and immune system disorders. The company’s research centers on harnessing the body’s innate immune response to address diseases that currently lack broadly effective treatments. Hemispherx’s principal commercial product is Alferon N Injection, an antiviral drug indicated for the treatment of external genital warts. Its lead investigational candidate is Ampligen® (rintatolimod), a synthetic RNA molecule designed as a toll-like receptor 3 agonist. Ampligen has been studied in conditions such as chronic fatigue syndrome (myalgic encephalomyelitis) and certain malignancies, and the company continues to advance clinical programs and regulatory activities around this immune-modulating therapy. Headquartered in Philadelphia, Pennsylvania, Hemispherx BioPharma operates primarily in the United States while pursuing strategic collaborations and regulatory approvals internationally. The company is led by President and Chief Executive Officer Thomas G. Equels, under whose guidance Hemispherx engages with government agencies, academic research centers and commercial partners to support its pipeline and expand its therapeutic reach.AI Generated. May Contain Errors. Read More Receive HEB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hemispherx BioPharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HEB Stock News HeadlinesHamilton ETFs Launches Hamilton Canadian Financials Index ETFJanuary 20, 2025 | businesswire.comH-E-B’s affordable grocery chain Joe V’s Smart Shop is coming to IrvingAugust 10, 2024 | dallasnews.comDWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain retirement accounts. Without the right strategy, these withdrawals can significantly increase your tax bill and shrink your nest egg. SmartAsset outlines six strategies that could help reduce your RMDs and potentially lower your tax burden. Their free tool can match you with vetted fiduciary financial advisors in your area—professionals legally bound to act in your best interest.September 10 at 2:00 AM | SmartAsset (Ad)Hemispherx Biopharma earnings preview: what Wall Street is expectingMay 15, 2024 | markets.businessinsider.comH-E-B hosting hiring fairsJanuary 7, 2024 | cbsnews.comH-E-B bets on loyal customers as it expands affordable Joe V’s storesOctober 3, 2023 | chron.comH-E-B enters the film world with a five-part docuseries covering Texas parks and wildlifeAugust 28, 2023 | chron.comH-E-B opens doors to new Georgetown grocery storeJuly 1, 2023 | bizjournals.comSee More Headlines HEB Stock Analysis - Frequently Asked Questions How have HEB shares performed this year? Hemispherx BioPharma's stock was trading at $0.2170 at the beginning of 2025. Since then, HEB shares have increased by 2,987.6% and is now trading at $6.70. How were Hemispherx BioPharma's earnings last quarter? Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) posted its quarterly earnings data on Thursday, August, 15th. The specialty pharmaceutical company reported ($1.07) EPS for the quarter, topping analysts' consensus estimates of ($1.70) by $0.63. The specialty pharmaceutical company earned $0.03 million during the quarter. When did Hemispherx BioPharma's stock split? Hemispherx BioPharma's stock reverse split on Tuesday, June 11th 2019.The 1-44 reverse split was announced on Friday, May 31st 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 10th 2019. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. How do I buy shares of Hemispherx BioPharma? Shares of HEB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Hemispherx BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Hemispherx BioPharma investors own include NewLink Genetics (NLNK), Goodrich Petroleum (GDPMQ), Biocept (BIOC), CTI BioPharma (CTIC), Inovio Pharmaceuticals (INO), Ayala Pharmaceuticals (ADXS). Company Calendar Last Earnings8/15/2019Today9/10/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNYSEAMERICAN:HEB Previous SymbolNYSE:HEB CIK946644 Webwww.hemispherx.net Phone+1-407-2718516FaxN/AEmployees31Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares2,442,000Free FloatN/AMarket Cap$16.36 million OptionableNot Optionable BetaN/A A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NYSEAMERICAN:HEB) was last updated on 9/10/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredWorld War 3? Everything Just Changed — and One Tiny Company Is at the Center of It.Trump immediately activated a $5.3 TRILLION AI missile shield — code-named Golden Dome — to stop drone swarms ...Angel Publishing | SponsoredLitecoin’s Creator Backs the World’s First TreasuryBitcoin's corporate adoption story has been written. Litecoin's is just beginning.The Tomorrow Investor | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hemispherx BioPharma, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Hemispherx BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
